FISHAWACK-HEALTH
8.4.2020 21:17:05 CEST | Business Wire | Press release
Fishawack Health , the global healthcare communications agency, announces the acquisition of Skysis , a boutique consulting firm providing integrated market access and commercial strategy solutions based in the US.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200408005692/en/
Skysis expertise bolsters Fishawack Health’s impressive consulting capabilities. The company brings with it the ability to connect interdependencies across healthcare professional (HCP), payer, channel, and patient stakeholders. It is the first acquisition with Fishawack Health’s new investor, Bridgepoint.
Oliver Dennis , Fishawack Health co-founder and CEO, said: “In partnering with Bridgepoint, we have made a step-change in our ambition. We’re delighted today to add Skysis to the group. They bring strategy and market access across the entire commercial life cycle, making them an important addition to our strategic consulting capabilities.”
Fred Bassett , Head of Consulting for Fishawack Health, added: “Skysis provides strategy and execution across every stage of the commercial life cycle. The company’s expertise bolsters Fishawack Health’s strong strategic consulting team, which includes analysts, researchers, commercial consultants, market access and customer experience specialists, and boasts a network of Physician Expert Partnerships.”
Providing further detail, Dan Twibell , Managing Director of Skysis, explained: “We wanted to partner with a group that could help us scale our business, offer more solutions to our clients and that our team would be excited to join.”
Dawn Rich , Managing Director of Skysis, said: “Our team is thrilled to be joining Fishawack Health. Our core capabilities match perfectly with the key services of the wider consulting capability.”
Fairmount Partners, a leading investment bank focused on pharmaceutical services businesses, introduced the parties identifying that Skysis’ four core practice areas – market access, new product planning /launch excellence, market insights, brand management and engagement – were a perfect match with Fishawack Health’s capabilities.
Established in 2001, Fishawack Health has become one of the largest independent healthcare communications organisations in the world. It has 14 offices across Europe and the US, and a highly skilled workforce of 850 employees. It serves more than 100 customers across 300 different drug compounds, including the top 20 global pharmaceutical companies and a range of innovative biotech and medical device companies.
Its three areas of specialism – strategic consulting and market access, medical communications, and commercial and creative execution – are underpinned by shared world-class resources. This includes digital expertise, insight, data analytics and visualisation, and media and production capabilities. These capabilities work independently or combine seamlessly as one unit, complete with teams tailored to the client’s individual needs and challenges.
Fishawack Health’s strategic and scientific focus makes it ideally placed to solve complex brand, portfolio, and enterprise-level challenges for its clients.
With experience across every major therapeutic category, Fishawack Health understands what it takes to improve patient outcomes and drive business success for its clients. The company will continue to add new capabilities designed to solve its clients’ critical medical and commercial challenges in an integrated and seamless way.
About Fishawack Health
Fishawack Health is an independent, full-service, global healthcare communications group with over 850 medical experts, marketing professionals, and strategic specialists. The organisation has three areas of specialism that work independently or as a single united team – strategic consulting and market access, medical communications, and commercial/creative execution.
About Skysis
Skysis is a boutique consulting firm that provides integrated commercial solutions to the biopharmaceutical industry. The organisation leverages their deep industry experience to generate insights and approaches that address their clients’ unique commercial needs.
Advisers involved in this transaction included:
KPMG Manchester acted on behalf of Fishawack Health for corporate finance and financial & tax due diligence; Addleshaw Goddard, Manchester and Sheppard Mullin, San Diego provided legal support. KPMG, Fairmount Partners, a leading investment bank focused on pharmaceutical services businesses, introduced the parties and acted as financial advisor to Skysis. Ulber & Berne LLP provided legal support.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200408005692/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BRUNO to Showcase Acclaimed Lifestyle and Travel Collections at Ambiente 20262.2.2026 09:00:00 CET | Press release
Tokyo-based lifestyle company BRUNO, Inc. (Headquarters: Shinjuku-ku, Tokyo; President & CEO: Tetsu Shiota), dedicated to the planning, development, and sale of lifestyle products, is pleased to announce its participation in Ambiente—the world’s leading international consumer goods trade fair held in Frankfurt, Germany. The company will showcase its two flagship brands: "BRUNO," a lifestyle brand dedicated to "enjoying life to the fullest," and "MILESTO," a premium travel brand designed for those who "live every day like a journey." This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260202663769/en/ Our participation in Ambiente marks a pivotal step in our global expansion strategy, as outlined in our current medium-term management plan. We are excited to introduce BRUNO and MILESTO—brands that have earned immense loyalty in Japan—to a global audience. Our exhibit showcases a curated selection of flagship products and latest inn
Reges Elektrik Acquires the Demirli Wind Power Plant, One of Türkiye’s Most Significant Wind Energy Projects2.2.2026 09:00:00 CET | Press release
Reges Elektrik, a dynamic and innovative leader in the Turkish energy sector, has announced the acquisition of Tuşpa Enerji Üretim A.Ş. as part of its strategic growth roadmap. Through this landmark acquisition, Reges Elektrik will launch electricity production at the 70 MW Demirli Wind Power Project, located in the Kaman district of Kırşehir. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126059611/en/ From left to right: Enver Altuncu, General Manager and Board Member at Reges Elektrik; Cansu Ünal Öngören, CFO and Board Member at Reges Elektrik; Geert Dooms, General Manager at RES Türkiye; Kağan Gilik, Deputy General Manager at RES Türkiye. Acquired from RES Türkiye, a subsidiary of RES Group—the world’s largest independent renewable energy company—the Demirli Project represents a pivotal milestone in Reges Elektrik’s decisive expansion into energy production. With this investment, the company scales its operations to i
Teledyne FLIR Defense Wins $17.5 Million Contract from armasuisse to Deliver Black Hornet 4 Nano-Drones for Dismounted and Vehicle-Integrated Reconnaissance2.2.2026 08:00:00 CET | Press release
Delivery of the Black Hornet UAV systems to Swiss Armed Forces will include drones with software and integration kit specially designed to work with Piranha 8x8 vehicle digital infrastructureWork shows promise and market potential for UAS armored vehicle integrations to enhance tactical operations Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE:TDY), announced that it has received a $17.5 million contract from armasuisse, the Swiss Federal Office of Defence Procurement, to deliver a large number of Black Hornet® 4 Personal Reconnaissance Systems, one of the world’s most advanced and widely deployed nano-drones. Black Hornet 4 was selected as an airborne dismountable Intelligence, Surveillance, and Reconnaissance (ISR) capability sensor for armasuisse’s Piranha 8x8 Armored engineering vehicle program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260201061637/en/ Teledyne FLIR Defense has won a $17.5
Danish C-UAS Startup Shotling Raises €700K Oversubscribed Pre-Seed (Myriad-IPO CLUB-EIFO) for Anti-Drone Shotgun2.2.2026 07:35:00 CET | Press release
Shotling, a Danish defense technology startup specializing in kinetic short-range counter-UAS (C-UAS) systems, today announced the closing of a pre-seed financing round with €700K committed out of a targeted €500K. The round is led by Myriad Defense Fund, with co-investment from IPO CLUB’s Fund II America 2030, and a non-dilutive match-loan granted by EIFO, the Export and Investment Fund of Denmark, supporting Shotling’s mission to deliver rapid-fire modular shotgun systems against FPV drones and loitering munitions—as the global counter-UAS market accelerates towards $10B by 2030, with kinetic defense segment showing strong momentum (25%+ CAGR). Shotling’s rotary shotgun system provides unmatched close-range defense (50–100m) against the rapidly growing threat of kamikaze drones, combining a gatling-style design, with novel, high-capacity magazines, and firing rates up to 3,000 RPM using standard or tungsten-based 12-gauge shells. With deep expertise in weapons engineering and active
Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 07:00:00 CET | Press release
The United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults RelabotulinumtoxinA is designed to optimize molecule integrity to deliver fast onset of action as early as Day 1 and sustained results for six months for frown lines and crow’s feet and has been approved in over 20 markets, including in the European Union1-3 Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
